Hepatalin hormone named the missing link in type 2 diabetes, prediabetes, and obesity
WINNIPEG, CANADA — 1 March 2023 — The Canadian Journal of Physiology and Pharmacology has published a review by Dr. W. Wayne Lautt that names hepatalin, a previously unknown hormone, the missing link in type 2 diabetes, prediabetes, and obesity. The review describes hepatalin’s role in health and disease.
“Since the discovery of insulin 100 years ago, the paradigm for dealing with diabetes has focused only on insulin,” says Dr. W. Wayne Lautt, co-founder and chief scientific officer of Scimar. “Our research shows insulin isn’t working alone.”
Like insulin, hepatalin reduces excess glucose in the body. But unlike insulin, which is produced by the pancreas and stores excess glucose in fat, hepatalin is produced by the liver and stores excess glucose in muscle. This discovery shows there are now two known hormones that play a major role in reducing elevated blood sugar levels.
This discovery is based on 30 years of research by Dr. W. Wayne Lautt. He’s been advancing his research over the last three decades, redefining how type 2 diabetes can be prevented, detected, and treated.
Through the lens of hepatalin, Scimar has conceived four products designed to enhance human health and manage type 2 diabetes. The products are at different development stages.
Dr. Lautt’s review is available here: https://cdnsciencepub.com/doi/abs/10.1139/cjpp-2022-0332.